Indaptus Therapeutics is trading 6.96% down at $1.20 after continued profit-taking following its 46.81% surge on August 20 and 6.52% decline on August 21.
- No fresh company-specific announcement was identified for August 24; the latest corporate update was second-quarter results released August 13.
- The decline appears primarily sector-related, reflecting reduced momentum after the recent spike.
- Broader pre-market sentiment is cautious, with Nasdaq futures down 0.58%, though secondary to biotech weakness.